Equillium, Inc.

EQ

US29446K1060

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.71 ^USD	-5.52%		+6.21%	+136.51%

Apr. 02	H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating	MT
Apr. 01	Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	CI

Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 25, 2024 at 04:11 pm EDT

Equillium, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 36.08 million compared to USD 15.76 million a year ago. Net loss was USD 13.34 million compared to USD 62.43 million a year ago.

Basic loss per share from continuing operations was USD 0.38 compared to USD 1.85 a year ago.

Latest news about Equillium, Inc.

H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating	Apr. 02	MT
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	Apr. 01	CI
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	Mar. 26	DJ
Equillium Swings to Q4 Loss As Revenue Falls	Mar. 25	MT
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Equillium, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25	CI
Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M	Mar. 25	MT
HC Wainwright Adjusts Price Target on Equillium to $4 From $4.50, Keeps Buy Rating	Dec. 26	MT
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 21	CI
HC Wainwright Adjusts Equillium's Price Target to $4.50 From $5.50, Maintains Buy Rating	Nov. 13	MT
Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology	Nov. 13	CI
Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.	Nov. 08	CI
Equillium, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (EQ) EQUILLIUM Reports Q3 Revenue $8.9M	Nov. 08	MT
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology	Nov. 06	CI
Transcript : Equillium, Inc. - Analyst/Investor Day	23-10-16
Equillium, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Earnings Flash (EQ) EQUILLIUM Posts Q2 Revenue $9.1M	23-08-09	MT
Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer	23-08-09	CI
Equillium Board Approves $7.5 Million Share Buyback Program	23-08-03	MT
Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.	23-08-02	CI
Equillium, Inc. authorizes a Buyback Plan.	23-08-01	CI
Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 3000E Growth Index	23-06-23	CI
Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 3000E Value Index	23-06-23	CI
Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 3000E Index	23-06-23	CI

Chart Equillium, Inc.

Duration

Period

More charts

Company Profile

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Companyâs pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Companyâs EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Equillium, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.71 USD

Average target price

6.75 USD

Spread / Average Target

+294.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EQUILLIUM, INC.	+136.51%	60.29M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Equillium, Inc.

Equities

EQ

US29446K1060

Pharmaceuticals

Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

EPS Revisions